Cerebrovascular Diseases

 

Secondary Prevention of Stroke and the Expanding Role of the Neurologist

Alberts M.J.

Author affiliations

Department of Neurology, Northwestern University Medical School, Chicago, Ill., USA

Keywords: Antiplatelet agentsStroke

Related Articles for ""
Cerebrovasc Dis 2002;13(suppl 1):12–16
https://doi.org/10.1159/000047784

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: January 18, 2002
Issue release date: 2002

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Abstract

Stroke is the leading cause of adult disability and dependency in western society. Following stroke, the risk of myocardial infarction (MI) is increased by a factor of around 2–3 compared with baseline. Indeed, after the first 30 days, stroke survivors are more likely to die from a cardiac event than from a cerebrovascular event. In patients with atherothrombotic stroke, preventing subsequent manifestations of the underlying disease is therefore an important therapeutic goal. A number of options have been shown to reduce the risk of stroke. Aggressively controlling stroke risk factors, such as hypertension, diabetes and smoking, should provide significant benefit in reducing stroke risk; however, it is difficult to realize the full potential of these approaches in routine clinical practice. A number of classes of medication can reduce the risk of stroke and other vascular events, including antiplatelet agents, anticoagulants, angiotensin-converting enzyme inhibitors and statins. Several antiplatelet agents are approved to reduce the risk of recurrent stroke, although only clopidogrel and acetylsalicylic acid (ASA) are approved for the reduction of both stroke and MI in such patients. In the CAPRIE study, clopidogrel showed a statistically significant relative risk reduction of 8.7% (p = 0.043) compared with ASA for the composite endpoint of ischaemic stroke, MI or vascular death. Evidence from animal studies, ex vivo models in humans, and patients undergoing coronary stent insertion or patients with unstable angina/non-Q-wave MI clearly demonstrates the synergistic antiplatelet effect of using clopidogrel with ASA. In summary, most patients with an ischaemic stroke should be treated with an antiplatelet agent to reduce their risk of recurrent stroke, MI, or vascular death. The use of aggressive antiplatelet therapy has the potential to become a new paradigm for managing patients with vascular disease due to atherothrombosis.

© 2002 S. Karger AG, Basel



Related Articles:

References

  1. American Heart Association: 2001 Heart and Stroke Statistical Update. Dallas, American Heart Association, 2000.
  2. Rothwell PM, Warlow CP: Prediction of benefit from carotid endarterectomy in individual patients: A risk-modelling study. Lancet 1999;353:2105–2111.
    External Resources
  3. Yadav JS: Management practices in carotid stenting. Cerebrovasc Dis 2001;11(suppl 2):18–22.
  4. Kannel WB, Wolf PA, Verter J: Manifestations of coronary disease predisposing to stroke: The Framingham Study. JAMA 1983;250:2942–2946.
    External Resources
  5. Viitanen M, Eriksson S, Asplund K: The risk of recurrent stroke, myocardial infarction, and epilepsy during long-term follow-up after stroke. Eur Neurol 1988;28:227–231.
    External Resources
  6. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
    External Resources
  7. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569–1581.
    External Resources
  8. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R, on behalf of the CAST and IST Collaborative Groups: Indications for early aspirin use in acute ischemic stroke. A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000;31:1240–1249.
    External Resources
  9. Algra A, van Gijn J: Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999;66:255.
  10. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339.
    External Resources
  11. Easton JD: Benefit of clopidogrel in patients with symptomatic cerebrovascular disease. Neurology 1998;50(suppl 4):A157.
  12. Gent M: Clopidogrel, a new potent adenosine diphosphate (ADP) receptor antagonist for the prevention of myocardial infarction and ischemic stroke. Todays Ther Trends 1998;16:237–254.
  13. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel compared with aspirin. Am Heart J 2000;140:67–73.
    External Resources
  14. Rupprecht HJ: Consistency of the benefit of clopidogrel across a range of vascular-related endpoints: Results from CAPRIE. Eur Heart J 1998;19(abstract suppl):52.
  15. Easton JD: Net benefit of clopidogrel over aspirin for the prevention of atherothrombotic events. Cerebrovasc Dis 1998;8(suppl 4):46.
  16. Hacke W: From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002;13(suppl 1):22–26.
  17. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Superiority of clopidogrel versus aspirin in patients with a history of diabetes mellitus. J Am Coll Cardiol 2000;35(suppl A):409.
  18. Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH, for the CLASSICS Investigators: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624–629.
    External Resources
  19. Berger PB: Clopidogrel instead of ticlopidine after coronary stent placement: Is the switch justified? Am Heart J 2000;140:354–358.
    External Resources
  20. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
    External Resources
  21. Harker LA, Marzec UM, Kelly AB, Chronos NRF, Sundell IB, Hanson SR, Herbert J-M: Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461–2469.
    External Resources
  22. Herbert J-M, Dol F, Bernat A, Falotico R, Lalé A, Savi P: The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998;80:512–518.
    External Resources
  23. Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, Shah PK, Forrester JS, Herbert JM, Litvack F: Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998;19:1538–1546.
    External Resources
  24. Harker LA, Boissel JP, Pilgrim AJ, Gent M, on behalf of the CAPRIE Steering Committee and Investigators: Comparative safety and tolerability of clopidogrel and aspirin. Results from CAPRIE. Drug Saf 1999;21:328–335.
  25. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.
    External Resources
  26. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.
    External Resources
  27. Wilterdink JL, Easton JD: Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999;56:1087–1092.
    External Resources
  28. Department of Health and Human Services, Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labelling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register 1998;63:56802–56819 (Docket No. 77N-094A).
  29. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 2001;119(1 suppl):194S–206S.
  30. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119(1 suppl):220S–227S.
  31. Cairns JA, Théroux P, Lewis HD Jr, Ezekowitz M, Meade TW: Antithrombotic agents in coronary artery disease. Chest 2001;119(1 suppl):228S–252S.
  32. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449–1457.
    External Resources
  33. Hart RG, Sherman DG, Easton JD, Cairns JA: Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998;51:674–681.
    External Resources
  34. Chimowitz MI: Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study. Stroke 2000;31:2536.
    External Resources
  35. The WARSS Clinical Trial Group: The Warfarin-Aspirin Recurrent Stroke Study (WARSS): Initial results. Stroke 2001;32:329-a.
  36. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–153.
    External Resources
  37. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Engl J Med 1991;325:445–453.
    External Resources
  38. Barnett HJM, Taylor W, Eliasziw M, Fox AJ, Ferguson GG, Haynes B, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, for the North American Symptomatic Carotid Endarterectomy Trial Collaborators: Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415–1425.
    External Resources
  39. Alberts MJ: Results of a multicenter prospective randomized trial of carotid artery stenting vs. carotid endartectomy. Stroke 2001;32:325.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: January 18, 2002
Issue release date: 2002

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2002, Vol.13, Suppl. 1

2002

Article

Recommend This
TOP